search
Back to results

Results of FilmArray® Gastro-intestinal Panel and Serum Procalcitonin in Acute Colitis and Infectious Diarrhea in the ER (PRODIARRAY)

Primary Purpose

Acute Diarrhea, Acute Colitis of Presumed Infectious Origin

Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Filmarray PCR multiplex-PCT assay
Sponsored by
Assistance Publique - Hôpitaux de Paris
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Acute Diarrhea focused on measuring Infectious Diarrhea, Colitis, PCR multiplex, PCT

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Inclusion criteria for patients presenting an acute diarrhoea :

  1. Patients over 18 years of age,
  2. Signed informed consent form
  3. Having a social security insurance,
  4. Attending the emergency department for Acute diarrhoea (at least three loose or liquid stools a day for less than 15 days)
  5. For whom a blood test in the emergency department is ordered as a standard of care

Inclusion criteria for patients presenting an infectious colitis :

  1. Patients over 18 years of age,
  2. Signed informed consent form
  3. Having a social security insurance,
  4. Attending the emergency department for a documented colitis presumed to be of infectious origin, for whom a blood test in the emergency department is planned, defined by:

    1. at least one of the following symptoms: abdominal pain, fever, diarrhoea and
    2. Elevated white blood cell count (> 10.000/mm3) or CRP (> 10 mg/l) and
    3. An abdominal CT scan showing a thickening of at least segmental colonic walls.

Exclusion Criteria:

  1. Recent abdominal surgery of less than one month
  2. Pregnancy
  3. Inflammatory bowel disease
  4. Patients under curatorship or guardianship

Sites / Locations

  • Pitié Salpetriere

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Acute diarrhoea or colitis presumed to be of infectious origin

Arm Description

Outcomes

Primary Outcome Measures

PCT concentration according to each type of pathogens identified using GI panel and stool cultures (bacteria, virus, parasites).
The median PCT concentration will be reported in the three main etiological group (viruses, bacteria, parasites) identified by stool culture and GI panel

Secondary Outcome Measures

Positivity rate and distribution of pathogens identified by the GI panel and stool culture
Positivity Rate of GI Panel and stool culture given in percentage (%) and the distribution of pathogens found if positive, divided in 3 groups (virus, bacteria and parasites)
Rate of antibiotic therapy initiated in the ER and in the first following 15 days
Rate of antibiotics use given in percentage (%)
Number of days of antibiotic exposure at day 15
Number of days on antibiotics for each patient
Rate of antibiotics prescription before and after results of the GI panel and PCT (Day 1)
Rate (%) of intention to start an antibiotic before the results of the GI panel and rate (%) of antibiotic's prescription after the results of the GI panel and PCT

Full Information

First Posted
January 17, 2020
Last Updated
January 24, 2022
Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
Biofire
search

1. Study Identification

Unique Protocol Identification Number
NCT04237181
Brief Title
Results of FilmArray® Gastro-intestinal Panel and Serum Procalcitonin in Acute Colitis and Infectious Diarrhea in the ER
Acronym
PRODIARRAY
Official Title
Results of FilmArray® Gastro-intestinal Panel (GI Panel) and Serum Procalcitonin (PCT) in Acute Colitis and Infectious Diarrhea in the Emergency Department.
Study Type
Interventional

2. Study Status

Record Verification Date
January 2022
Overall Recruitment Status
Completed
Study Start Date
March 9, 2020 (Actual)
Primary Completion Date
March 24, 2020 (Actual)
Study Completion Date
December 23, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
Biofire

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Acute diarrhea and acute colitis of infectious origin are common reasons for consultation at the emergency department. The current etiological diagnostic approach is limited to the determination of markers of inflammation, such as CRP and blood leukocytes, which lack specificity and sensitivity for bacterial infection. The stool culture can detect bacterial pathogens in the stool with a result at least 48 hours later and a positivity rate <50%. This study will describe the procalcitonin (PCT) concentrations (a biomarker of bacterial infection) in this population to evaluate its usefulness depending on the viral or bacterial etiology identified by stool multiplex gastro-intestinal PCR panel (GI panel) and stool culture. The investigators hypothesize that PCT levels will be higher if the GI panel or the stool culture identifies a bacteria or a parasite, as it is the case in respiratory tract infections. If there is a detection of a virus by the GI panel or both the stool culture and the GI panel are negative, the investigators expect that PCT values will be lower or negative. the investigators will include the patients admitted to the ED with a suspicion of infectious diarrhea or acute colitis in order to have a large representative panel of infectious diarrhea etiologies. Only the patients having a blood sample prescribed as the routine care will be included. The blood sample is useful for dosing CRP and whole blood cell count (WBC), which are part of current biologic analyses performed in this context. After getting the patient's consent, the investigator will add the PCT dosage in blood sampling and will ask the patient to provide a stool sample, in order to have a stool culture and to perform an extended investigation for the pathogens through multiplex PCR technology (Filmarray ®GI panel). The physician will be asked if all these results (the ones ordered currently together with the dosage of PCT and the GI panel) will change his/her decision to start an antibiotic. Patients will receive a phone call at day 15 after their initial admission in the emergency department and will be asked if he/she has consulted a new physician or if a new treatment by antibiotics was started. Data collection procedures: Data from the medical file will be collected by the investigators and the emergency department clinical research assistant. All the data will be pseudonymized. The collection will be done at the day of admission in the emergency department and after the phone interview at Day15.
Detailed Description
Acute diarrhea and acute colitis of infectious origin are common reasons for consultation at the emergency department. The current etiological diagnostic approach is limited to the determination of markers of inflammation, such as CRP and blood leukocytes, which lack specificity and sensitivity for bacterial infection. The stool culture can detect bacterial pathogens in the stool with a result at least 48 hours later and a positivity rate <50%. This study will describe the procalcitonin (PCT) concentrations (a biomarker of bacterial infection) in this population to evaluate its usefulness depending on the viral or bacterial etiology identified by stool multiplex gastro-intestinal PCR panel (GI panel) and stool culture. The investigators hypothesize that PCT levels will be higher if the GI panel or the stool culture identifies a bacteria or a parasite, as it is the case in respiratory tract infections. If there is a detection of a virus by the GI panel or both the stool culture and the GI panel are negative, the investigators expect that PCT values will be lower or negative. The investigators will include the patients admitted to the ED with a suspicion of infectious diarrhea or acute colitis in order to have a large representative panel of infectious diarrhea etiologies. Only the patients having a blood sample prescribed as the routine care will be included. The blood sample is useful for dosing CRP and whole blood cell count (WBC), which are part of current biologic analyses performed in this context. After getting the patient's consent, the investigator will add the PCT dosage in blood sampling and will ask the patient to provide a stool sample, in order to have a stool culture and to perform an extended investigation for the pathogens through multiplex PCR technology (Filmarray ®GI panel). The physician will be asked if all these results (the ones ordered currently together with the dosage of PCT and the GI panel) will change his/her decision to start an antibiotic. Patients will receive a phone call at day 15 after their initial admission in the emergency department and will be asked if he/she has consulted a new physician or if a new treatment by antibiotics was started. Data collection procedures: Data from the medical file will be collected by the investigators and the emergency department clinical research assistant. All the data will be pseudonymized. The collection will be done at the day of admission in the emergency department and after the phone interview at Day15. Statistical justification for sample size: This will be a pilot study to describe the results of PCT concentration and multiplex GI panel. As to our knowledge, there is no published study reporting PCT concentrations in this population. This preclude a sample, size calculation. The investigators will include as much patients as possible during one year in order to cover the epidemiological seasonal variations and to obtain a convenient sample of at least 100 patients. Statistical methods description: Clinical and biological data will be reported as median and interquartile range or mean +/- SD. PCT values will be reported as median and IQR, respectively if a there is a viral infection, a documented infection (bacterium or parasite) or no pathogen identified by GI panel and/or stool culture (bacteria). Patient's characteristics and PCT results will be compared in all groups, using as a reference, the group where no pathogen is observed. A sub-group analysis will be performed on colitis and acute diarrhea respectively, to find out if there is any difference with the variables analyzed as both pathologies are not managed in the same way.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Diarrhea, Acute Colitis of Presumed Infectious Origin
Keywords
Infectious Diarrhea, Colitis, PCR multiplex, PCT

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
128 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Acute diarrhoea or colitis presumed to be of infectious origin
Arm Type
Other
Intervention Type
Device
Intervention Name(s)
Filmarray PCR multiplex-PCT assay
Intervention Description
Filmarray PCR multiplex gastro intestinal panel on stools and serum PCT dosage
Primary Outcome Measure Information:
Title
PCT concentration according to each type of pathogens identified using GI panel and stool cultures (bacteria, virus, parasites).
Description
The median PCT concentration will be reported in the three main etiological group (viruses, bacteria, parasites) identified by stool culture and GI panel
Time Frame
Day 1
Secondary Outcome Measure Information:
Title
Positivity rate and distribution of pathogens identified by the GI panel and stool culture
Description
Positivity Rate of GI Panel and stool culture given in percentage (%) and the distribution of pathogens found if positive, divided in 3 groups (virus, bacteria and parasites)
Time Frame
Day 1
Title
Rate of antibiotic therapy initiated in the ER and in the first following 15 days
Description
Rate of antibiotics use given in percentage (%)
Time Frame
Day 1 and 15
Title
Number of days of antibiotic exposure at day 15
Description
Number of days on antibiotics for each patient
Time Frame
Day 15
Title
Rate of antibiotics prescription before and after results of the GI panel and PCT (Day 1)
Description
Rate (%) of intention to start an antibiotic before the results of the GI panel and rate (%) of antibiotic's prescription after the results of the GI panel and PCT
Time Frame
Day 1

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Inclusion criteria for patients presenting an acute diarrhoea : Patients over 18 years of age, Signed informed consent form Having a social security insurance, Attending the emergency department for Acute diarrhoea (at least three loose or liquid stools a day for less than 15 days) For whom a blood test in the emergency department is ordered as a standard of care Inclusion criteria for patients presenting an infectious colitis : Patients over 18 years of age, Signed informed consent form Having a social security insurance, Attending the emergency department for a documented colitis presumed to be of infectious origin, for whom a blood test in the emergency department is planned, defined by: at least one of the following symptoms: abdominal pain, fever, diarrhoea and Elevated white blood cell count (> 10.000/mm3) or CRP (> 10 mg/l) and An abdominal CT scan showing a thickening of at least segmental colonic walls. Exclusion Criteria: Recent abdominal surgery of less than one month Pregnancy Inflammatory bowel disease Patients under curatorship or guardianship
Facility Information:
Facility Name
Pitié Salpetriere
City
Paris
ZIP/Postal Code
75012
Country
France

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Results of FilmArray® Gastro-intestinal Panel and Serum Procalcitonin in Acute Colitis and Infectious Diarrhea in the ER

We'll reach out to this number within 24 hrs